Literature DB >> 18940747

Risk-reduction surgery in BRCA mutation carriers in a Spanish population: adherence and results.

Pedro Pérez Segura1, Paula Jiménez, Helena Olivera, Raquel Andrés Conejero, Trinidad Caldés, Miguel de la Hoya, Jose María Román, Arancha Moreno, Javier Puente, Eduardo Díaz-Rubio.   

Abstract

OBJECTIVE: To analyse the level of adherence to prophylactic surgery of breast and/or ovarian cancer in female carriers of the BRCA1 or BRCA2 mutation in a referential genetic counselling unit in Spain.
METHODS: Between January 1998 and November 2006, a total of 684 families with several cases of breast and/or ovarian cancer were selected by the Genetic Counselling Unit at the Hospital Clínico Universitario San Carlos. Some of them opted for prophylactic surgery after genetic counselling and genetic testing.
RESULTS: The pathogenic mutation was found in 57 families out of a total of 449 families who fulfilled the hereditary breast/ovarian cancer criteria. Out of a total of 238 individuals who were carriers of the mutation, 136 (57%) were offered risk-reducing prophylactic surgery. Prophylactic surgery was chosen by 58 (43%) women out of a total of 136 who were offered this possibility; the histological findings observed 7% malignant lesions in the breast and, in the ovarian-fallopian complex, 2 cases (8%) of a borderline tumour and one case (4%) of papillary adenocarcinoma.
CONCLUSION: This is the first study published on the role of prophylactic surgery in BRCA mutation carriers in the Spanish population. The incidence of occult carcinoma in these cases is lower than in other series.

Entities:  

Mesh:

Year:  2008        PMID: 18940747     DOI: 10.1007/s12094-008-0267-9

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  29 in total

1.  Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation.

Authors:  H Meijers-Heijboer; B van Geel; W L van Putten; S C Henzen-Logmans; C Seynaeve; M B Menke-Pluymers; C C Bartels; L C Verhoog; A M van den Ouweland; M F Niermeijer; C T Brekelmans; J G Klijn
Journal:  N Engl J Med       Date:  2001-07-19       Impact factor: 91.245

2.  Screening women at high risk for breast cancer with mammography and magnetic resonance imaging.

Authors:  Constance D Lehman; Jeffrey D Blume; Paul Weatherall; David Thickman; Nola Hylton; Ellen Warner; Etta Pisano; Stuart J Schnitt; Constantine Gatsonis; Mitchell Schnall; Gia A DeAngelis; Paul Stomper; Eric L Rosen; Michael O'Loughlin; Steven Harms; David A Bluemke
Journal:  Cancer       Date:  2005-05-01       Impact factor: 6.860

3.  Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.

Authors:  Bernard Fisher; Joseph P Costantino; D Lawrence Wickerham; Reena S Cecchini; Walter M Cronin; Andre Robidoux; Therese B Bevers; Maureen T Kavanah; James N Atkins; Richard G Margolese; Carolyn D Runowicz; Joan M James; Leslie G Ford; Norman Wolmark
Journal:  J Natl Cancer Inst       Date:  2005-11-16       Impact factor: 13.506

4.  Selective use of sentinel lymph node surgery during prophylactic mastectomy.

Authors:  Judy C Boughey; Nazanin Khakpour; Funda Meric-Bernstam; Merrick I Ross; Henry M Kuerer; Sonja E Singletary; Gildy V Babiera; Banu Arun; Kelly K Hunt; Isabelle Bedrosian
Journal:  Cancer       Date:  2006-10-01       Impact factor: 6.860

5.  Effect of prevention strategies on survival and quality-adjusted survival of women with BRCA1/2 mutations: an updated decision analysis.

Authors:  Victor R Grann; Judith S Jacobson; Dustin Thomason; Dawn Hershman; Daniel F Heitjan; Alfred I Neugut
Journal:  J Clin Oncol       Date:  2002-05-15       Impact factor: 44.544

6.  Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers.

Authors:  Lauren Scheuer; Noah Kauff; Mark Robson; Bridget Kelly; Richard Barakat; Jaya Satagopan; Nathan Ellis; Martee Hensley; Jeff Boyd; Patrick Borgen; Larry Norton; Kenneth Offit
Journal:  J Clin Oncol       Date:  2002-03-01       Impact factor: 44.544

7.  Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.

Authors:  Noah D Kauff; Jaya M Satagopan; Mark E Robson; Lauren Scheuer; Martee Hensley; Clifford A Hudis; Nathan A Ellis; Jeff Boyd; Patrick I Borgen; Richard R Barakat; Larry Norton; Mercedes Castiel; Khedoudja Nafa; Kenneth Offit
Journal:  N Engl J Med       Date:  2002-05-20       Impact factor: 91.245

Review 8.  Prevention of breast cancer in women who carry BRCA1 or BRCA2 mutations: a critical review of the literature.

Authors:  Ronit Calderon-Margalit; Ora Paltiel
Journal:  Int J Cancer       Date:  2004-11-10       Impact factor: 7.396

9.  Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition.

Authors:  Mieke Kriege; Cecile T M Brekelmans; Carla Boetes; Peter E Besnard; Harmine M Zonderland; Inge Marie Obdeijn; Radu A Manoliu; Theo Kok; Hans Peterse; Madeleine M A Tilanus-Linthorst; Sara H Muller; Sybren Meijer; Jan C Oosterwijk; Louk V A M Beex; Rob A E M Tollenaar; Harry J de Koning; Emiel J T Rutgers; Jan G M Klijn
Journal:  N Engl J Med       Date:  2004-07-29       Impact factor: 91.245

10.  Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study.

Authors:  U Veronesi; P Maisonneuve; A Costa; V Sacchini; C Maltoni; C Robertson; N Rotmensz; P Boyle
Journal:  Lancet       Date:  1998-07-11       Impact factor: 79.321

View more
  1 in total

Review 1.  Through the glass darkly: intraepithelial neoplasia, top-down differentiation, and the road to ovarian cancer.

Authors:  Christopher P Crum; Michael Herfs; Gang Ning; Jonathan G Bijron; Brooke E Howitt; Cynthia A Jimenez; Suchanan Hanamornroongruang; Frank D McKeon; Wa Xian
Journal:  J Pathol       Date:  2013-12       Impact factor: 7.996

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.